Literature DB >> 30843635

Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma.

Jeon Yeob Jang1, Deok-Soo Kim2, Hee-Young Park2, Sung-Chan Shin2, Wonjae Cha2, Jin-Choon Lee3, Soo-Geun Wang2, Byung-Joo Lee2.   

Abstract

BACKGROUND: This study aimed to investigate the relationships between serum vascular endothelial growth factor (VEGF)-A or VEGF-C levels and lymph node metastasis (LNM) status in patients with papillary thyroid carcinoma (PTC).
METHODS: The study enrolled 150 patients with pathologically proven PTC who underwent surgery: PTC without LNM, PTC with central neck metastasis, and PTC with lateral neck metastasis.
RESULTS: Preoperative serum VEGF-A levels were 300.12 ± 80.80 pg/mL overall and were not correlated with the presence of LNM. Preoperative serum VEGF-C levels were 132.41 ± 48.48 pg/mL overall and were significantly correlated with the presence of LNM. Serum VEGF-C levels were further increased in patients with lateral neck metastasis and positively correlated with the number of metastatic LNs (rho = 0.252, P = 0.002). Serum VEGF-C, but not VEGF-A, was identified as a significant predictor of lateral neck metastasis.
CONCLUSION: Serum VEGF-C might be a clinically relevant biomarker of lateral neck metastasis in patients with PTC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  lateral neck metastasis; lymph node metastasis; papillary thyroid carcinoma; serum VEGF-C

Mesh:

Substances:

Year:  2019        PMID: 30843635     DOI: 10.1002/hed.25729

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  Nomograms based on preoperative multimodal ultrasound of papillary thyroid carcinoma for predicting central lymph node metastasis.

Authors:  Quan Dai; Dongmei Liu; Yi Tao; Chao Ding; Shouqiang Li; Chen Zhao; Zhuo Wang; Yangyang Tao; Jiawei Tian; Xiaoping Leng
Journal:  Eur Radiol       Date:  2022-02-28       Impact factor: 5.315

2.  Prophylactic central lymph node dissection performed selectively with cN0 papillary thyroid carcinoma according to a risk-scoring model.

Authors:  Xiang Zhong; Yunpeng Lu; Xu Yin; Quhui Wang; Feiran Wang; Zhixian He
Journal:  Gland Surg       Date:  2022-02

3.  Identification of soluble tissue-derived biomarkers from human thyroid tissue explants maintained on a microfluidic device.

Authors:  Andrew Riley; Heidi Jones; James England; Dmitriy Kuvshinov; Victoria Green; John Greenman
Journal:  Oncol Lett       Date:  2021-09-13       Impact factor: 2.967

4.  The Specifically Androgen-Regulated Gene (SARG) Promotes Papillary Thyroid Carcinoma (PTC) Lymphatic Metastasis Through Vascular Endothelial Growth Factor C (VEGF-C) and VEGF Receptor 3 (VEGFR-3) Axis.

Authors:  Shuai-Jun Xu; Bin Jin; Wei-Jun Zhao; Xue-Xian Chen; Ying-Ying Tong; Xiao-Fei Ding; Ying-Yuan Chen; Dong-Hao Wang; Zhi-Ming Wang; Bing-Qing Dai; Sai Chen; Yong Liang; Guang Chen; Su-Jiao Pan; Ling-Long Xu
Journal:  Front Oncol       Date:  2022-06-13       Impact factor: 5.738

5.  Clinical Study of Ultrasonographic Risk Factors for Central Lymph Node Metastasis of Papillary Thyroid Carcinoma.

Authors:  Yang Guang; Wen He; Wei Zhang; Hongxia Zhang; Yukang Zhang; Fang Wan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

6.  Ultrasonic Characteristics Improve Prediction of Central Lymph Node Metastasis in cN0 Unifocal Papillary Thyroid Cancer.

Authors:  Yongchen Liu; Jianhao Huang; Zhiyuan Zhang; Yijie Huang; Jialin Du; Sanming Wang; Zeyu Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.